nct_id,title,phase,status,study_type,conditions,interventions,molecular_targets,sponsor,collaborators,enrollment_count,start_date,completion_date,locations,needs_review,source_url
NCT01174121,"A Phase II Study Using Short-Term Cultured, Autologous Tumor-Infiltrating Lymphocytes Following a Lymphodepleting Regimen in Metastatic Cancers Plus the Administration of Pembrolizumab",Phase 2,Recruiting,Interventional,Metastatic Colorectal Cancer; Metastatic Pancreatic Cancer; Metastatic Ovarian Cancer; Metastatic Breast Carcinoma; Metastatic Endocrine Tumors/ Neuroendocrine Tumors,Pembrolizumab (Keytruda); Fludarabine; Cyclophosphamide; Aldesleukin; Young TIL,,National Cancer Institute (NCI),,332,2010-08-26,2029-12-27,United States,No,https://clinicaltrials.gov/study/NCT01174121
NCT01638676,A Phase I/II Trial of Vemurafenib and Metformin to Unresectable Stage IIIC and Stage IV BRAF.V600E+ Melanoma Patients,Phase 1/Phase 2,Recruiting,Interventional,Melanoma,Vemurafenib; Metformin,,University of Louisville,James Graham Brown Cancer Center,55,2012-07-05,2027-06-05,United States,No,https://clinicaltrials.gov/study/NCT01638676
NCT02012699,Integrated Cancer Repository for Cancer Research,,Recruiting,Observational,Pancreatic Cancer; Thyroid Cancer; Lung Cancer; Esophageal Cancer; Thymus Cancer; Colon Cancer; Rectal Cancer; Gastrointestinal Stromal Tumors; Anal Cancer; Bile Duct Cancer; Duodenal Cancer; Gallbladder Cancer; Gastric Cancer; Liver Cancer; Small Intestine Cancer; Peritoneal Surface Malignancies; Familial Adenomatous Polyposis; Lynch Syndrome; Bladder Cancer; Kidney Cancer; Penile Cancer; Prostate Cancer; Testicular Cancer; Ureter Cancer; Urethral Cancer; Hypopharyngeal Cancer; Laryngeal Cancer; Lip Cancer; Oral Cavity Cancer; Nasopharyngeal Cancer; Oropharyngeal Cancer; Paranasal Sinus Cancer; Nasal Cavity Cancer; Salivary Gland Cancer; Skin Cancer; Central Nervous System Tumor; Central Nervous System Cancer; Mesothelioma; Breast Cancer; Leukemia; Melanoma; Sarcoma; Unknown Primary Tumor; Multiple Myeloma; Ovarian Cancer; Endometrial Cancer; Vaginal Cancer; Neuroendocrine Tumors; Plasma Cell Dyscrasia; Healthy Control,,,University of Nebraska,,999999,2013-11-01,2099-12-05,United States,No,https://clinicaltrials.gov/study/NCT02012699
NCT02485847,IRIS Registry: Intelligent Research in Sight Registry,,Recruiting,Observational,Eye Diseases,Ophthalmology,,American Academy of Ophthalmology,,20000000,2014-03-05,2100-01-05,United States,No,https://clinicaltrials.gov/study/NCT02485847
NCT02670707,Randomization of Cytarabine Monotherapy Versus Standard-of-Care Vinblastine/Prednisone for Frontline Treatment of Langerhans Cell Histiocytosis (TXCH LCH0115),Phase 3,Recruiting,Interventional,Langerhans Cell Histiocytosis,Cytarabine; Vinblastine/prednisone,,Baylor College of Medicine,,124,2016-03-07,2029-01-05,United States,No,https://clinicaltrials.gov/study/NCT02670707
NCT02693535,Targeted Agent and Profiling Utilization Registry (TAPUR) Study,Phase 2,Recruiting,Interventional,"Lymphoma, Non-Hodgkin; Multiple Myeloma; Advanced Solid Tumors",Palbociclib; Sunitinib; Temsirolimus; Trastuzumab and Pertuzumab; Vemurafenib and Cobimetinib; Regorafenib; Olaparib; Pembrolizumab; Nivolumab and Ipilimumab; Abemaciclib; Talazoparib; Atezolizumab and PHESGO; Atezolizumab and Talazoparib; Entrectinib; Larotrectinib; Tucatinib plus Trastuzumab Subcutaneous (SC); Futibatinib,,American Society of Clinical Oncology,"AstraZeneca; Bayer; Bristol-Myers Squibb; Eli Lilly and Company; Genentech, Inc.; Merck Sharp & Dohme LLC; Pfizer; Boehringer Ingelheim; Seagen Inc.; Taiho Oncology, Inc.",4200,2016-03-14,2028-12-31,United States,No,https://clinicaltrials.gov/study/NCT02693535
NCT03042221,Early Rebiopsy to Identify Mechanisms and Biomarkers of Tumor Cell Survival Following Systemic Therapy for Lung Cancer,,Recruiting,Observational,"Non-Small Cell Carcinoma of Lung, TNM Stage 4; Non-Small Cell Lung Cancer; EGFR Gene Mutation; ALK Gene Mutation; ROSE Cluster 1; BRAF V600E",,,"University of Colorado, Denver",,100,2016-05-10,2027-09-30,United States,No,https://clinicaltrials.gov/study/NCT03042221
NCT03254667,"Prospective, Observational Study Brodalumab Compared With Other Therapies in the Treatment of Adults With Moderate-to-Severe Psoriasis Who Are Candidates for Systemic Therapy or Phototherapy in the Course of Actual Clinical Care",,Enrolling by invitation,Observational,Psoriasis,Brodalumab; Comparator Drug (non-biologic IL-17 inhibitors),,"Bausch Health Americas, Inc.",,3500,2017-07-25,2031-11-05,United States,No,https://clinicaltrials.gov/study/NCT03254667
NCT03420963,Ex-Vivo Expanded Allogeneic NK Cells for the Treatment of Solid Tumors of Pediatric Origin in Children and Young Adults,Phase 1,Recruiting,Interventional,Recurrent Cutaneous Melanoma; Recurrent Lip and Oral Cavity Carcinoma; Recurrent Malignant Endocrine Neoplasm; Recurrent Malignant Female Reproductive System Neoplasm; Recurrent Malignant Male Reproductive System Neoplasm; Recurrent Malignant Mesothelioma; Recurrent Malignant Neoplasm of Multiple Primary Sites; Recurrent Malignant Oral Neoplasm; Recurrent Malignant Pharyngeal Neoplasm; Recurrent Malignant Skin Neoplasm; Recurrent Malignant Soft Tissue Neoplasm; Recurrent Malignant Solid Neoplasm; Recurrent Malignant Thyroid Gland Neoplasm; Recurrent Malignant Urinary System Neoplasm; Refractory Cutaneous Melanoma; Refractory Malignant Bone Neoplasm; Refractory Malignant Endocrine Neoplasm; Refractory Malignant Female Reproductive System Neoplasm; Refractory Malignant Male Reproductive System Neoplasm; Refractory Malignant Mesothelioma; Refractory Malignant Neoplasm of Multiple Primary Sites; Refractory Malignant Oral Neoplasm; Refractory Malignant Pharyngeal Neoplasm; Refractory Malignant Skin Neoplasm; Refractory Malignant Soft Tissue Neoplasm; Refractory Malignant Solid Neoplasm; Refractory Malignant Thyroid Gland Neoplasm; Refractory Malignant Urinary System Neoplasm,Cord Blood-derived Expanded Allogeneic Natural Killer Cells; Cyclophosphamide; Etoposide,,M.D. Anderson Cancer Center,National Cancer Institute (NCI),38,2018-08-31,2027-12-01,United States,No,https://clinicaltrials.gov/study/NCT03420963
NCT03474497,"UCDCC#272: A Phase I/II Study of Intralesional IL-2, Hypofractionated Radiotherapy, and Pembrolizumab in Patients Refractory to Standard-of-Care PD-1/PD-L1 Checkpoint Blockade",Phase 1/Phase 2,Recruiting,Interventional,Non Small Cell Lung Cancer; Metastatic Melanoma; Metastatic Renal Cell Carcinoma; Head and Neck Squamous Cell Carcinoma,IL-2; Pembrolizumab; Radiotherapy,,"Megan Daly, MD",Merck Sharp & Dohme LLC,45,2019-05-20,2023-12-05,United States,No,https://clinicaltrials.gov/study/NCT03474497
NCT03567889,"An Open-Label, Randomized, Controlled Multi-Center Study of The Efficacy of Daromun (L19IL2 + L19TNF) Neoadjuvant Intratumoral Treatment Followed by Surgery and Adjuvant Therapy Versus Surgery and Adjuvant Therapy in Clinical Stage IIIB/C/D Melanoma Patients",Phase 3,Recruiting,Interventional,Melanoma Stage IIIB; Melanoma Stage IIIC; Melanoma Stage IIID,Daromun; Surgery; Adjuvant therapy,,Philogen S.p.A.,,186,2018-09-20,2031-12-05,Spain; Switzerland; United States,No,https://clinicaltrials.gov/study/NCT03567889
NCT03568630,A Longitudinal Cohort Study to Identify Clinical and Blood Markers of Early Pancreas Cancer,,Recruiting,Observational,"Diabetes Mellitus, Type 2; PreDiabetes; Pancreas Cyst; Chronic Pancreatitis; Genetic Predisposition to Disease; Inherited Disease",,,University of Nebraska,National Cancer Institute (NCI); Virginia Mason Hospital/Medical Center; VA Nebraska Western Iowa Health Care System,1250,2018-07-26,2028-07-05,United States,No,https://clinicaltrials.gov/study/NCT03568630
NCT03743298,Phase 1B Trial of AV-MEL-1 (Autologous Dendritic Cells Loaded With Autologous Tumor Antigens) With Anti-PD-1 Checkpoint Inhibitors in Metastatic Melanoma,Phase 1,Recruiting,Interventional,Metastatic Melanoma,AV-MEL-1,,"Aivita Biomedical, Inc.",,20,2021-04-21,2026-05-05,United States,No,https://clinicaltrials.gov/study/NCT03743298
NCT03803553,Early Identification and Treatment of Occult Metastatic Disease in Stage III Colon Cancer,Phase 3,Recruiting,Interventional,Metastatic Colon Cancer; Stage III Colon Cancer,FOLFIRI Protocol; ACTIVE SURVEILLANCE; Nivolumab Protocol; Encorafenib/Binimetinib/Cetuximab Protocol; Trastuzumab + Pertuzumab,,Massachusetts General Hospital,Stand Up To Cancer,400,2020-04-16,2027-12-05,United States,No,https://clinicaltrials.gov/study/NCT03803553
NCT03851445,LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study),Phase 2/Phase 3,Recruiting,Interventional,Previously Treated Non-Small Cell Lung Cancer,Screening Platform,,SWOG Cancer Research Network,National Cancer Institute (NCI),10000,2019-02-06,2029-01-28,United States,No,https://clinicaltrials.gov/study/NCT03851445
NCT04079179,"A Phase 2 Study to Assess the Safety and Efficacy of Cobimetinib in Refractory Langerhans Cell Histiocytosis, LCH-Associated Neurodegenerative Disease, and Other Histiocytic Disorders.",Phase 2,Recruiting,Interventional,"Langerhan's Cell Histiocytosis; Juvenile Xanthogranuloma; Erdheim-Chester Disease; Rosai Dorfman Disease; Neuro-Degenerative Disease; Histiocytic Sarcoma; Histiocytic Disorders, Malignant",Cobimetinib,,Carl Allen,"Baylor College of Medicine; North American Consortium for Histiocytosis; Genentech, Inc.",90,2021-04-19,2029-12-05,United States,No,https://clinicaltrials.gov/study/NCT04079179
NCT04166409,A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1),Phase 3,Recruiting,Interventional,Low Grade Astrocytoma; Low Grade Glioma; Metastatic Low Grade Astrocytoma; Metastatic Low Grade Glioma; WHO Grade 1 Glioma; WHO Grade 2 Glioma,Biospecimen Collection; Carboplatin; Echocardiography Test; Magnetic Resonance Imaging; Questionnaire Administration; Selumetinib Sulfate; Vincristine Sulfate,,National Cancer Institute (NCI),,170,2020-01-31,2030-12-31,Canada; Puerto Rico; United States,No,https://clinicaltrials.gov/study/NCT04166409
NCT04314401,Cancer Moonshot Biobank Research Protocol,,Recruiting,Observational,Acute Myeloid Leukemia; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Clinical Stage IV Esophageal Adenocarcinoma AJCC v8; Clinical Stage IV Gastric Cancer AJCC v8; Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8; Esophageal Carcinoma; Fallopian Tube Carcinoma; Gastric Carcinoma; Hormone Receptor-Positive Breast Carcinoma; Invasive Breast Carcinoma; Lung Non-Small Cell Carcinoma; Lung Small Cell Carcinoma; Malignant Solid Neoplasm; Melanoma; Metastatic Prostate Carcinoma; Multiple Myeloma; Ovarian Carcinoma; Ovarian High Grade Serous Adenocarcinoma; Primary Peritoneal Carcinoma; Stage III Fallopian Tube Cancer AJCC v8; Stage III Lung Cancer AJCC v8; Stage III Ovarian Cancer AJCC v8; Stage IV Colorectal Cancer AJCC v8; Stage IV Fallopian Tube Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IV Ovarian Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8; Triple-Negative Breast Carcinoma,Biospecimen Collection; Computed Tomography; Magnetic Resonance Imaging; Medical Chart Review; Paracentesis; Positron Emission Tomography,,National Cancer Institute (NCI),,1600,2020-11-11,2027-04-30,Puerto Rico; United States,No,https://clinicaltrials.gov/study/NCT04314401
NCT04423029,"A Phase 1/1b, First-In-Human, Multi-Part, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF6002 as a Monotherapy and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications",Phase 1,Recruiting,Interventional,Solid Tumors,DF6002; Nivolumab,,Dragonfly Therapeutics,,438,2020-07-13,2027-11-30,Australia; France; Spain; United States,No,https://clinicaltrials.gov/study/NCT04423029
NCT04474301,Well-Being and Quality of Life in Melanoma Patients During COVID-19 Pandemic,,Recruiting,Observational,COVID-19 Infection; Melanoma,Survey Administration,,M.D. Anderson Cancer Center,National Cancer Institute (NCI),1152,2020-06-11,2026-12-30,United States,No,https://clinicaltrials.gov/study/NCT04474301
NCT04513028,Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma,Not Applicable,Recruiting,Interventional,Melanoma Stage III; Melanoma Stage IV,Beta-Glucan,,Kelly McMasters,,30,2020-11-03,2027-01-15,United States,No,https://clinicaltrials.gov/study/NCT04513028
NCT04697576,Intralesional Influenza Vaccine for Patients With Melanoma,Phase 1,Recruiting,Interventional,Clinical Stage I Cutaneous Melanoma AJCC v8; Clinical Stage IA Cutaneous Melanoma AJCC v8; Clinical Stage IB Cutaneous Melanoma AJCC v8; Clinical Stage II Cutaneous Melanoma AJCC v8; Clinical Stage IIA Cutaneous Melanoma AJCC v8; Clinical Stage IIB Cutaneous Melanoma AJCC v8; Clinical Stage IIC Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Metastatic Melanoma,Ipilimumab; Nivolumab; Pembrolizumab; Quadrivalent Inactivated Influenza Vaccine; Resection; Nivolumab + Relatlimab,,Carlo Contreras,,36,2021-10-20,2026-12-31,United States,No,https://clinicaltrials.gov/study/NCT04697576
NCT04712877,LEADER Neoadjuvant Screening Trial: LCMC4 Evaluation of Actionable Drivers in Early Stage Lung Cancers,,Recruiting,Observational,NSCLC,"ctDNA, tumor NGS",,Lung Cancer Mutation Consortium,Lung Cancer Research Foundation,1000,2022-06-15,2026-06-15,United States,No,https://clinicaltrials.gov/study/NCT04712877
NCT04844528,Randomized Phase 2 Studying the Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia (CLL) With History of Non-melanoma Skin Cancers (NMSC),Phase 2,Recruiting,Interventional,Chronic Lymphocytic Leukemia; Non-melanoma Skin Cancer (NMSC),Nicotinamide; Placebo,,University of Utah,Huntsman Cancer Institute,86,2022-02-25,2028-08-05,United States,No,https://clinicaltrials.gov/study/NCT04844528
NCT04899908,"A Double-blind, Phase II Randomized Study of Brain-directed Stereotactic Radiation With or Without AGuIX Gadolinium-based Nanoparticles in the Management of Brain Metastases at Higher Risk of Local Recurrence With Radiation Alone",Phase 2,Recruiting,Interventional,Brain Cancer; Brain Metastases; Melanoma; Lung Cancer; Breast Cancer; HER2-positive Breast Cancer; Colorectal Cancer; Gastrointestinal Cancer; SRS; SRT; Whole Brain Radiation; Stereotactic Radiation; AGuIX; Nanoparticle; Cystic; Brain Tumor,Stereotactic Radiation; AGuIX gadolinium-based nanoparticles; Placebo,,Dana-Farber Cancer Institute,NH TherAguix SAS,134,2021-09-15,2026-02-05,United States,No,https://clinicaltrials.gov/study/NCT04899908
NCT04970056,Pancreatic Cancer Early Detection Consortium,,Recruiting,Observational,Pancreas Cancer; Pancreas Cyst; Pancreatic Ductal Adenocarcinoma; Genetic Predisposition,,,Arbor Research Collaborative for Health,,10000,2020-09-18,2030-12-31,Australia; Canada; Hungary; Iceland; Israel; Italy; Singapore; Spain; Taiwan; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT04970056
NCT04971499,A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma,Phase 1/Phase 2,Recruiting,Interventional,Melanoma,Dapansutrile; Pembrolizumab,,"April Salama, M.D.",Merck Sharp & Dohme LLC; Olatec Therapeutics LLC,26,2022-09-06,2026-04-30,United States,No,https://clinicaltrials.gov/study/NCT04971499
NCT05009992,"A Combination Therapy Trial Using an Adaptive Platform Design for Children and Young Adults With Diffuse Midline Gliomas (DMGs) Including Diffuse Intrinsic Pontine Gliomas (DIPGs) at Initial Diagnosis, Post-Radiation Therapy and at Time of Progression",Phase 2,Recruiting,Interventional,"Diffuse Intrinsic Pontine Glioma; Diffuse Midline Glioma, H3 K27M-Mutant; Recurrent Diffuse Intrinsic Pontine Glioma; Recurrent Diffuse Midline Glioma, H3 K27M-Mutant; Recurrent WHO Grade III Glioma; WHO Grade III Glioma",ONC201; Radiation Therapy; Paxalisib; DNX-2401,,"University of California, San Francisco",The Chad-Tough Defeat DIPG Foundation; Mithil Prasad Foundation; Storm the Heavens Fund; National Institute of Neurological Disorders and Stroke (NINDS); Jazz Pharmaceuticals; Neeve Kolte and Brave Ronil Foundation; Will Meeker Foundation; CV Biomanufacturing,360,2021-10-20,2029-06-30,Australia; Israel; Netherlands; New Zealand; Switzerland; United States,No,https://clinicaltrials.gov/study/NCT05009992
NCT05077137,A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy,Phase 1,Recruiting,Interventional,Melanoma,Tetanus Diptheria Vaccine; Polio Boost Immunization,,Duke University,,25,2021-09-07,2026-09-01,United States,No,https://clinicaltrials.gov/study/NCT05077137
NCT05225428,Video Education With Result Dependent dIsclosure,Not Applicable,Recruiting,Interventional,Genetic Testing; Breast Cancer; Ovarian Cancer; Pancreatic Cancer; Prostate Cancer; Colorectal Cancer; Renal Cancer; Melanoma; Sarcoma,Video Education; Genetic Counseling,,Dana-Farber Cancer Institute,National Cancer Institute (NCI); National Human Genome Research Institute (NHGRI),1020,2022-08-04,2026-09-01,United States,No,https://clinicaltrials.gov/study/NCT05225428
NCT05267626,"A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer",Phase 1/Phase 2,Recruiting,Interventional,Advanced Solid Tumor; Metastatic Cancer; Cutaneous Melanoma; Non-Small Cell Lung Cancer,AU-007; Aldesleukin; Avelumab; Nivolumab,,"Aulos Bioscience, Inc.",,159,2022-04-04,2026-06-12,Australia; United States,No,https://clinicaltrials.gov/study/NCT05267626
NCT05313243,Phase 2 Study of Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory CD30 Positive T-cell Lymphoma,Phase 2,Recruiting,Interventional,T-Cell Lymphoma,Brentuximab vedotin; Pembrolizumab,,Yale University,Merck Sharp & Dohme LLC,32,2023-07-10,2028-07-30,United States,No,https://clinicaltrials.gov/study/NCT05313243
NCT05503797,"A Phase 2 Master Protocol to Assess the Efficacy and Safety of FORE8394, an Inhibitor of BRAF Class 1 and Class 2 Alterations, in Participants With Cancer Harboring BRAF Alterations",Phase 2,Recruiting,Interventional,Cancer Harboring BRAF Alterations; HGG; LGG; Solid Tumors,Plixorafenib,,Fore Biotherapeutics,,254,2023-02-21,2026-12-28,Australia; Canada; France; Germany; Italy; Norway; South Korea; Spain; Sweden; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT05503797
NCT05538130,A PHASE 1A/B OPEN-LABEL MASTER STUDY OF PF-07799544 AS A SINGLE-AGENT AND IN COMBINATION WITH OTHER TARGETED AGENTS IN PARTICIPANTS WITH ADVANCED SOLID TUMORS,Phase 1,Recruiting,Interventional,Melanoma; Glioma; Thyroid Cancer; Non-Small Cell Lung Cancer; Malignant Neoplasms; Brain Neoplasms; Colorectal Cancer,PF-07799544; PF-07799933; encorafenib,,Pfizer,,124,2022-11-30,2028-10-11,Australia; Brazil; Canada; Israel; United States,No,https://clinicaltrials.gov/study/NCT05538130
NCT05562791,Pilot Study of 68Gallium PSMA-PET/CT in Patients With Metastatic Urothelial Carcinoma or Melanoma,Phase 1,Recruiting,Interventional,Bladder Cancer,[68Ga]PSMA; PET/CT imaging,,Memorial Sloan Kettering Cancer Center,,20,2022-09-28,2026-09-05,United States,No,https://clinicaltrials.gov/study/NCT05562791
NCT05576896,"A Single-Arm, Phase II Study of Autophagy Modulation Using Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in Metastatic BRAF-mutated Colorectal Cancer Refractory to Standard Therapies",Phase 2,Recruiting,Interventional,Stage IV Colorectal Cancer Positive for BRAF V600E Mutation; Colorectal Cancer; Colorectal Cancer Stage IV,Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab,,Northwestern University,National Cancer Institute (NCI),43,2022-10-10,2028-07-01,United States,No,https://clinicaltrials.gov/study/NCT05576896
NCT05607095,"A Pilot Trial of Autologous Tumor Infiltrating Lymphocytes (LN-144 or LN-145) for Patients With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma",Phase 1,Recruiting,Interventional,Uveal Melanoma; Melanoma; Metastatic Uveal Melanoma; Metastatic Melanoma,Lifileucel (LN-144/LN-145),,Memorial Sloan Kettering Cancer Center,"Iovance Biotherapeutics, Inc.",20,2022-11-01,2026-05-01,United States,No,https://clinicaltrials.gov/study/NCT05607095
NCT05684965,"A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX301 in Patients With Advanced Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,Advanced Solid Tumor,XTX301,,"Xilio Development, Inc.",,358,2023-05-11,2027-02-05,United States,No,https://clinicaltrials.gov/study/NCT05684965
NCT05694715,Combination Therapy of Niraparib and Irinotecan in Cancers With Mutations in DNA Repair Genes,Phase 1,Recruiting,Interventional,Metastatic Solid Tumor; BRCA1 Mutation; BRCA2 Mutation; ATM Gene Mutation; PALB2 Gene Mutation,Niraparib; Irinotecan,,"University of California, San Francisco",GlaxoSmithKline,24,2023-05-23,2028-01-31,United States,No,https://clinicaltrials.gov/study/NCT05694715
NCT05704647,Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases,Phase 2,Recruiting,Interventional,Melanoma (Skin),BMS-986213 (Relatlimab-Nivolumab FDC); Nivolumab; Relatlimab,,M.D. Anderson Cancer Center,,30,2023-02-23,2028-07-31,United States,No,https://clinicaltrials.gov/study/NCT05704647
NCT05786924,"A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies",Phase 1/Phase 2,Recruiting,Interventional,Non-small Cell Lung Cancer; Histiocytic Neoplasm; Histiocytosis; BRAF Gene Mutation; BRAF V600E; BRAF V600 Mutation; BRAF Mutation-Related Tumors; BRAF; Metastatic Lung Non-Small Cell Carcinoma; Metastatic Lung Cancer; Recurrent Lung Cancer; Recurrent Lung Non-Small Cell Carcinoma; NSCLC; Solid Tumor; Solid Carcinoma; KRAS G12D; KRAS G12V; KRAS Mutation-Related Tumors; NRAS Gene Mutation; Thyroid Cancer; Thyroid Carcinoma; Colorectal Cancer; Colorectal Carcinoma; Recurrent Histiocytic and Dendritic Cell Neoplasm; Brain Metastases; Recurrent NSCLC; KRAS G13C; Acquired Resistance to KRAS G12C Inhibitor; KRAS G12A; KRAS G12F; KRAS G12R; KRAS G13D,S241656; FOLFOX6/FOLFOX7; FOLFIRI; Cetuximab; Panitumumab; Gemcitabine; Nab-paclitaxel,,Institut de Recherches Internationales Servier,,554,2023-04-18,2028-06-05,United States,No,https://clinicaltrials.gov/study/NCT05786924
NCT05828069,Phase 2 Study of Tovorafenib (DAY101) in Relapsed and Refractory Langerhans Cell Histiocytosis,Phase 2,Recruiting,Interventional,Recurrent Langerhans Cell Histiocytosis; Refractory Langerhans Cell Histiocytosis,Biospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy; Computed Tomography; Echocardiography Test; FDG-Positron Emission Tomography and Computed Tomography Scan; Lumbar Puncture; Multigated Acquisition Scan; Tovorafenib,,National Cancer Institute (NCI),,48,2024-03-28,2028-09-30,Australia; Canada; United States,No,https://clinicaltrials.gov/study/NCT05828069
NCT05839912,Lymph Node Excision (LNEx) for Patients With Stage III Melanoma With One Clinically Positive Node: Excision of Lymph Node Trial [EXCILYNT],Not Applicable,Recruiting,Interventional,Melanoma,Excision of clinically detected lymph node metastasis before any systemic therapy; Excision of clinically detected lymph node metastasis after neoadjuvant systemic therapy,,"Craig L Slingluff, Jr",,66,2023-09-06,2028-09-01,United States,No,https://clinicaltrials.gov/study/NCT05839912
NCT05868629,Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors,,Recruiting,Observational,Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors,Non-investigational,,Novartis Pharmaceuticals,,40,2024-02-06,2028-03-03,United States,No,https://clinicaltrials.gov/study/NCT05868629
NCT05896839,A Phase 2 Study of Nivolumab and Ipilimumab in Combination With Sirolimus and Prednisone in Kidney Transplant Recipients With Selected Unresectable or Metastatic Cutaneous Cancers,Phase 1/Phase 2,Recruiting,Interventional,Clinical Stage III Cutaneous Melanoma AJCC v8; Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8; Clinical Stage IV Cutaneous Melanoma AJCC v8; Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8; Metastatic Basal Cell Carcinoma; Metastatic Carcinoma in the Skin; Metastatic Melanoma; Metastatic Merkel Cell Carcinoma; Metastatic Skin Squamous Cell Carcinoma; Unresectable Basal Cell Carcinoma; Unresectable Melanoma; Unresectable Merkel Cell Carcinoma; Unresectable Skin Squamous Cell Carcinoma,Biopsy Procedure; Biospecimen Collection; Computed Tomography; Ipilimumab; Kidney Biopsy; Magnetic Resonance Imaging; Nivolumab; Prednisone; Sirolimus,,National Cancer Institute (NCI),,16,2024-07-24,2027-01-31,United States,No,https://clinicaltrials.gov/study/NCT05896839
NCT05970497,"A Phase 1/2, Open-Label, Multi-Center, Dose Escalation and Expansion Study of KB707 in Subjects With Locally Advanced or Metastatic Solid Tumor Malignancies",Phase 1/Phase 2,Recruiting,Interventional,Cancer; Melanoma Stage III; Melanoma Stage IV; Cutaneous Melanoma,KB707; Opdualag; KEYTRUDA ®( Pembrolizumab),,"Krystal Biotech, Inc.",,240,2023-10-31,2027-07-05,United States,No,https://clinicaltrials.gov/study/NCT05970497
NCT06035744,"A Phase 1 First-in-Human Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamic Activity of CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Advanced Solid Tumor,CLN-617; Pembrolizumab,,Cullinan Therapeutics Inc.,,86,2023-12-12,2028-06-05,United States,No,https://clinicaltrials.gov/study/NCT06035744
NCT06074588,"A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy (Docetaxel or Pemetrexed) in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations",Phase 3,Recruiting,Interventional,Non-small Cell Lung Cancer (NSCLC),Sacituzumab tirumotecan; Docetaxel; Pemetrexed,,Merck Sharp & Dohme LLC,,556,2023-11-12,2030-03-11,Australia; Brazil; Canada; Chile; China; Czechia; France; Germany; Greece; Hong Kong; Israel; Italy; Japan; Malaysia; Mexico; Philippines; Poland; South Korea; Spain; Taiwan; Thailand; Turkey (Türkiye); United Kingdom; United States; Vietnam,No,https://clinicaltrials.gov/study/NCT06074588
NCT06102902,A Phase 1 Study of ZEN003694 (ZEN-3694) in Combination With Cetuximab and Encorafenib in Patients With Refractory BRAF V600E Metastatic Colorectal Cancer,Phase 1,Recruiting,Interventional,Metastatic Colorectal Adenocarcinoma; Recurrent Colorectal Adenocarcinoma; Refractory Colorectal Adenocarcinoma; Stage IV Colorectal Cancer AJCC v8,BET Bromodomain Inhibitor ZEN-3694; Biopsy Procedure; Biospecimen Collection; Cetuximab; Computed Tomography; Echocardiography Test; Encorafenib; Magnetic Resonance Imaging; Multigated Acquisition Scan,,National Cancer Institute (NCI),,30,2024-06-05,2027-01-30,United States,No,https://clinicaltrials.gov/study/NCT06102902
NCT06112314,"A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301",Phase 3,Recruiting,Interventional,Advanced Melanoma,Brenetafusp; Nivolumab; Nivolumab + Relatlimab,,Immunocore Ltd,,680,2024-06-05,2027-10-16,Argentina; Australia; Austria; Belgium; Brazil; Bulgaria; Canada; Czechia; Denmark; France; Germany; Hungary; Italy; Norway; Poland; Romania; Spain; Sweden; Switzerland; Turkey (Türkiye); United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT06112314
NCT06150664,"A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-8371 in Patients With Advanced Malignancies",Phase 1,Recruiting,Interventional,Non Small Cell Lung Cancer; Triple Negative Breast Cancer; Hodgkin Lymphoma; Head and Neck Squamous Cell Carcinoma; Malignant Melanoma,CTX-8371,,Compass Therapeutics,,73,2024-03-19,2027-05-05,United States,No,https://clinicaltrials.gov/study/NCT06150664
NCT06157099,A Decentralized Phase II Randomized Controlled Trial of Atorvastatin in Resected High-Risk Melanoma,Phase 2,Recruiting,Interventional,Pathologic Stage IIIA Cutaneous Melanoma AJCC v8; Pathologic Stage IIA Cutaneous Melanoma AJCC v8; Pathologic Stage IIB Cutaneous Melanoma AJCC v8,Atorvastatin; Placebo Administration; Computed Tomography; Magnetic Resonance Imaging; Electronic Health Record Review,,OHSU Knight Cancer Institute,Oregon Health and Science University; Kuni Foundation,150,2024-09-01,2029-09-01,United States,No,https://clinicaltrials.gov/study/NCT06157099
NCT06194929,"Phase 1b/2 Trial of Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma",Phase 1/Phase 2,Recruiting,Interventional,Cutaneous Melanoma; Brain Metastases,Defactinib; Avutometinib; Encorafenib,,University of Utah,"Verastem, Inc.",33,2024-03-20,2030-01-15,United States,No,https://clinicaltrials.gov/study/NCT06194929
NCT06270706,"A Phase 1a/1b Multicenter, Open-label Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of PLN-101095 as Monotherapy and in Combination With Pembrolizumab in Adult Participants With Advanced or Metastatic Solid Tumors Who Have Disease Progression While on Pembrolizumab",Phase 1,Recruiting,Interventional,Metastatic Solid Tumor,PLN-101095; Pembrolizumab,,"Pliant Therapeutics, Inc.",,77,2023-08-30,2025-12-05,United States,No,https://clinicaltrials.gov/study/NCT06270706
NCT06331377,Clinical and Molecular Characteristics of Histiocytic Disorders,,Recruiting,Observational,Histiocytic Disorder,Non-Interventional Study,,Mayo Clinic,,500,2017-07-27,2027-07-31,United States,No,https://clinicaltrials.gov/study/NCT06331377
NCT06440850,"A Pilot Clinical Trial of Vemurafenib and Cobimetinib as a Redifferentiation Strategy in High-Risk, Radioactive Iodine (RAI) Naïve, BRAFV600E Mutated Differentiated Thyroid Carcinoma Patients Undergoing Initial RAI Therapy",Phase 2,Recruiting,Interventional,Thyroid Gland Follicular Carcinoma; Thyroid Gland Oncocytic Carcinoma; Thyroid Gland Papillary Carcinoma,Biospecimen Collection; Cobimetinib; Computed Tomography; Diagnostic Imaging; I-131 Uptake Test; Iodine I-131; Magnetic Resonance Imaging; Positron Emission Tomography; Recombinant Thyrotropin Alfa; Ultrasound Imaging; Vemurafenib,,City of Hope Medical Center,National Cancer Institute (NCI),21,2024-07-15,2026-11-22,United States,No,https://clinicaltrials.gov/study/NCT06440850
NCT06466434,Prebiotic Food-enriched Diet (PreFED) to Enhance the Microbiome and Response to First-line Immunotherapy in Unresectable Melanoma,Not Applicable,Recruiting,Interventional,Unresectable Melanoma,Prebiotic Food-Enriched Diet,,M.D. Anderson Cancer Center,,75,2024-09-01,2029-06-30,United States,No,https://clinicaltrials.gov/study/NCT06466434
NCT06475807,Cancer Nutrition Study: CaNS - A Pilot Study of Dietary Interventions in Cancer Patients Treated With Immune Checkpoint Inhibitors,Not Applicable,Recruiting,Interventional,Cancer,High-fermented food; High fiber supplementation,,University of Pittsburgh,,60,2024-07-17,2027-06-05,United States,No,https://clinicaltrials.gov/study/NCT06475807
NCT06475989,A Randomized Phase III Study of BRAF-Targeted Therapy vs Cabozantinib in RAI-Refractory Differentiated Thyroid Cancer With BRAF V600Em,Phase 3,Recruiting,Interventional,Refractory Differentiated Thyroid Gland Carcinoma,Biospecimen Collection; Cabozantinib; Computed Tomography; Dabrafenib; Magnetic Resonance Imaging; Questionnaire Administration; Trametinib,,ECOG-ACRIN Cancer Research Group,National Cancer Institute (NCI),264,2024-08-22,2030-09-30,United States,No,https://clinicaltrials.gov/study/NCT06475989
NCT06582745,"Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib",Phase 2,Recruiting,Interventional,Langerhans Cell Histiocytosis,Trametinib,,Cook Children's Health Care System,,75,2024-06-24,2039-12-05,United States,No,https://clinicaltrials.gov/study/NCT06582745
NCT06585410,A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous Squamous Cell Carcinoma (CSCC),Phase 3,Recruiting,Interventional,Cutaneous Squamous Cell Carcinoma (CSCC),Cemiplimab; Standard of care,,Regeneron Pharmaceuticals,,369,2025-01-02,2030-05-03,Australia; United States,No,https://clinicaltrials.gov/study/NCT06585410
NCT06608511,Liquid Biomarker Study in Melanoma and Non-Melanoma Skin Cancers,,Recruiting,Observational,"Skin Cancer; Melanoma (Skin Cancer); Basal Cell Carcinoma of Skin; Basal Cell Carcinoma of Skin, Site Unspecified; Cutaneous Squamous Cell Carcinoma (CSCC); Merkel Cell Carcinoma of Skin",Blood draw for the laboratory assessment,,"University of Wisconsin, Madison",National Center for Advancing Translational Sciences (NCATS),20,2024-12-11,2026-12-05,United States,No,https://clinicaltrials.gov/study/NCT06608511
NCT06610682,Feasibility of CSF (Cerebrospinal Fluid) and Plasma ctDNA (Circulating Tumor Deoxyribonucleic) in BRAF (V-raf Murine Sarcoma Viral Oncogene Homolog B1)-Altered Glioma During Treatment With Plixorafenib,Early Phase 1,Recruiting,Interventional,BRAF V600E Mutation,Plixorafenib; Cobicistat 150 MG [Tybost],,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,Fore Biotherapeutics; Ivy Brain Tumor Foundation,15,2025-04-07,2027-06-30,United States,No,https://clinicaltrials.gov/study/NCT06610682
NCT06712875,A Pilot Study Evaluating the Toxicity and Clinical Benefit of Mitogen-activated Protein Kinase (MAPK) Pathway Inhibition Combined With Programmed Cell Death-1 Checkpoint Blockade (Anti-PD1) for the Treatment of BRAF-altered Pediatric Gliomas,Phase 1/Phase 2,Recruiting,Interventional,Low Grade Glioma; High Grade Glioma,"Trametinib and Nivolumab; Dabrafenib, trametinib, nivolumab",,Ann & Robert H Lurie Children's Hospital of Chicago,,27,2025-04-01,2029-06-05,United States,No,https://clinicaltrials.gov/study/NCT06712875
NCT06902376,NEO-COMBAT XL: Neoadjuvant and Maintenance XL092 and Cemiplimab in BRAF V600E-wildtype Anaplastic Thyroid Cancer: a Phase 1B Study,Phase 1,Recruiting,Interventional,Anaplastic Thyroid Cancer; Thyroid Cancer; BRAF Mutation-Related Tumors,Cemiplimab; XL092,,UNC Lineberger Comprehensive Cancer Center,Regeneron Pharmaceuticals; Exelixis,12,2025-06-03,2028-08-31,United States,No,https://clinicaltrials.gov/study/NCT06902376
NCT06910657,"A First-in-human, Phase I, Multi-center, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Evidence of Antitumor Activity of IDOV-Immune in Adult Participants With Advanced Solid Tumors",Phase 1,Recruiting,Interventional,Colorectal Cancer; Pancreatic Cancer; Melanoma; Ovarian Cancer; Gastric Cancer; Esophageal Cancer; Hepatocellular Carcinoma; Renal Cell Carcinoma; Breast Cancer; Sarcoma; Bladder Cancer; Lung Cancer; Prostate Cancer; Cervical Cancers; Head and Neck Cancers; Adrenal Gland Tumors,IDOV-Immune (oncolytic vaccinia virus),,"ViroMissile, Inc.",,78,2025-08-25,2027-05-31,Australia; United States,No,https://clinicaltrials.gov/study/NCT06910657
NCT06932757,Phase 2 Trial of Adjuvant Quisinostat in High-Risk Uveal Melanoma,Phase 2,Recruiting,Interventional,Uveal Melanoma,Quisinostat,,University of Miami,Viriom; Joseph and Florence Mandel Family Foundation,63,2025-05-27,2030-05-27,United States,No,https://clinicaltrials.gov/study/NCT06932757
NCT06975293,"Open-label, Non-randomized, Multi-cohort, Phase 1b/2 Trial Investigating the Safety, Tolerability, and Antitumor Activity of STC-15 (a METTL3 Inhibitor) as a Part of Combination Therapy With Toripalimab in Participants With Selected Advanced Cancers",Phase 1/Phase 2,Recruiting,Interventional,Metastatic Non-small Cell Lung Cancer; Metastatic Melanoma; Metastatic Endometrial Cancer; Metastatic Head-and-neck Squamous-cell Carcinoma; Solid Tumor,STC-15 in combination with toripalimab,,STORM Therapeutics LTD,"Coherus Oncology, Inc.",188,2025-05-05,2026-01-29,United States,No,https://clinicaltrials.gov/study/NCT06975293
NCT07015190,"A Randomized, Phase 3, Open-label Study of Neoadjuvant Darovasertib in Subjects With Primary Non-metastatic Uveal Melanoma (OptimUM-10)",Phase 3,Recruiting,Interventional,Uveal Melanoma,Darovasertib; Primary Local Therapy,,IDEAYA Biosciences,,520,2025-10-05,2031-03-05,Australia; Austria; Belgium; Canada; Czechia; Denmark; Estonia; France; Germany; Greece; Israel; Italy; Netherlands; Poland; Spain; Switzerland; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT07015190
NCT07023731,"A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ARV-806 in Participants With KRAS G12D Mutated Advanced Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,KRAS G12D Mutation; Advanced Solid Cancer,ARV-806,,Arvinas Inc.,,159,2025-05-29,2029-04-02,United States,No,https://clinicaltrials.gov/study/NCT07023731
NCT07049276,Randomized Controlled Trial of Selective Index Lymph Node Resection Versus Therapeutic Lymph Node Dissection After Neoadjuvant Immunotherapy for Stage IIIB-D Melanoma,Not Applicable,Recruiting,Interventional,"Cutaneous Melanoma, Stage III",Index lymph node resection; Therapeutic lymph node dissection,,Melanoma Institute Australia,,1500,2025-10-01,2040-08-05,Australia; Canada; Italy; New Zealand; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT07049276
NCT07070232,"A Phase I/II, Open-label, Adaptive Two-part Trial to Evaluate the Safety, Efficacy, Optimal Dose and Pharmacokinetics of BNT326 as Monotherapy and in Combination With Cancer Immunotherapies in Participants With Advanced Solid Tumors",Phase 1/Phase 2,Recruiting,Interventional,Advanced Solid Tumor,BNT326; BNT327; Itraconazole; Paroxetine,,BioNTech SE,,550,2025-08-12,2030-02-05,Australia; United Kingdom; United States,No,https://clinicaltrials.gov/study/NCT07070232
NCT07148245,Characterization of the Symptom Experience of Patients With Cutaneous Melanoma Receiving Immune Checkpoint Inhibitor Therapy,,Recruiting,Observational,"Cutaneous Melanoma; Cutaneous Melanoma, Stage III; Cutaneous Melanoma by AJCC V7 Stage; Cutaneous Melanoma, Stage IV",Blood Sample; Health Related Quality of Life Questionnaires (HRQoL); Medical Chart Review,,"University of California, San Francisco",National Cancer Institute (NCI),300,2025-10-13,2027-06-30,United States,No,https://clinicaltrials.gov/study/NCT07148245
NCT07223424,Patient Preference for Subcutaneous vs. Intravenous Immune Therapy (PSI-Immune),Phase 2,Recruiting,Interventional,Renal Cell Carcinoma; Non Small Cell Lung Cancer; Melanoma; Colo-rectal Cancer (dMMR/MSI-H CRC); Hepatocellular Carcinoma; Ulcerative Colitis; Esophageal Cancer; Squamous Cell Carcinoma; Gastric/GEJ; Cervical Cancer; Gastro-Esophageal Adenocarcinoma; Esophageal Adenocarcinoma,nivolumab; pembrolizumab,,Diwakar Davar,,480,2025-11-04,2030-11-30,United States,No,https://clinicaltrials.gov/study/NCT07223424
NCT07237100,A Pilot Study of Mirdametinib in Patients With Advanced Melanoma With an NF1 Mutation,Phase 2,Recruiting,Interventional,Advanced Unresectable Melanoma; Metastatic Melanoma,Mirdametinib,,"Kevin Kim, MD",,10,2025-10-13,2030-10-13,United States,No,https://clinicaltrials.gov/study/NCT07237100
